| #42 |
Gerald Michael Loughney |
Air Products And Chemicals |
1 |
| #42 |
Michael T. MCCABE |
Glaxosmithkline |
1 |
| #42 |
Jerry L. Adams |
Smithkline Beecham Limited |
1 |
| #42 |
Philip Anthony Harris |
Smithkline Beecham Limited |
1 |
| #42 |
Louis Lafrance |
Glaxosmithkline |
1 |
| #42 |
Robert E. Mack |
General Instrument |
1 |
| #42 |
William Duffield |
Institute For Musculoskeletal Science And Education |
1 |
| #42 |
Derek Norton |
BOE |
1 |
| #42 |
John Kenneth McDonough, IV |
Drexel University |
1 |
| #42 |
Kimberly N. Smitheman |
Glaxosmithkline |
1 |
| #42 |
Gopinath Ganji |
Glaxosmithkline |
1 |
| #42 |
David F. Brumbaugh |
Arris Enterprises |
1 |
| #42 |
Patrick M. Eidam |
Glaxosmithkline Intellectual Property Development Limited |
1 |
| #42 |
Jon M. Wigginton |
Bristol-Myers Squibb |
1 |
| #42 |
Linda M. Hand |
— |
1 |
| #42 |
Colby Barth |
Juniper Networks |
1 |
| #42 |
Mahase Nardeo |
Medical Components |
1 |
| #42 |
John W. Carosi |
Unl Holdings |
1 |
| #42 |
Joshi M. Ramanjulu |
Glaxosmithkline Intellectual Property Development Limited |
1 |
| #42 |
Edward J. McShane, III |
Institute For Musculoskeletal Science And Education |
1 |
| #42 |
Thomas D. Boris |
Streamlight |
1 |
| #42 |
Brendan M. Crowley |
Merck |
1 |
| #42 |
Omar Abdelfattah Abu-Baker |
Glaxosmithkline |
1 |
| #42 |
Gerald Kuehl |
Animas |
1 |
| #42 |
Sharad Kumar Verma |
Glaxosmithkline |
1 |
| #42 |
Charles William Blackledge, Jr. |
Glaxosmithkline Intellectual Property (No. 4) Limited |
1 |
| #42 |
Donald Frederick Wright |
Rohm And Haas |
1 |
| #42 |
Marcia V. Fournier |
— |
1 |
| #42 |
Yiqian Lian |
Glaxosmithkline Intellectual Property Development Limited |
1 |
| #42 |
Dai-Shi Su |
Sloan Kettering Institute For Cancer Research |
1 |
| #42 |
Frederick H. Fiesser |
Glaxosmithkline |
1 |
| #42 |
James Alan Sago |
Accellent |
1 |
| #42 |
Bryan Wayne King |
Glaxosmithkline Intellectual Property Development Limited |
1 |
| #42 |
Kenneth A. Newlander |
Smithkline Beecham Limited |
1 |
| #42 |
Freddie L. Singleton |
Dow Global Technologies |
1 |
| #42 |
Mark Schulz |
Johnson & Johnson |
1 |
| #42 |
Glen Spreitzer |
Johnson Matthey Public Limited |
1 |
| #42 |
Maurice P. DeYoung |
Five Prime Therapeutics |
1 |
| #42 |
Joseph P. McGonigal |
— |
1 |
| #42 |
David Schweitzer |
Intel |
1 |
| #42 |
Sean Patrick Hoelzle |
Sprint Communications |
1 |
| #42 |
Jessica R. Sinacola |
Merck |
1 |
| #42 |
Jae U. Jeong |
Glaxosmithkline Intellectual Property Development Limited |
1 |
| #42 |
Joseph E. Pero |
Glaxosmithkline Intellectual Property Development Limited |
1 |
| #42 |
Stephen A. Koch |
Certainteed |
1 |
| #42 |
Jeffrey Rowe |
Honeywell |
1 |
| #42 |
James Bushong |
Carbo-Ua Limited |
1 |
| #42 |
Jonathan C. Barth |
Juniper Networks |
1 |
| #42 |
Stuart Paul Romeril |
Glaxosmithkline |
1 |
| #42 |
Saswati Pujari |
Dow Global Technologies |
1 |